Teresa Brophy Bair Sells 11,208 Shares of Kura Oncology (NASDAQ:KURA) Stock

Kura Oncology, Inc. (NASDAQ:KURA) insider Teresa Brophy Bair sold 11,208 shares of the firm’s stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $8.46, for a total transaction of $94,819.68. Following the completion of the sale, the insider owned 226,931 shares of the company’s stock, valued at $1,919,836.26. This trade represents a 4.71% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Teresa Brophy Bair also recently made the following trade(s):

• On Friday, November 14th, Teresa Brophy Bair sold 8,804 shares of Kura Oncology stock. The stock was sold at an average price of $11.18, for a total value of $98,428.72.

Kura Oncology Stock Performance

KURA opened at $8.04 on Thursday. Kura Oncology, Inc. has a 12-month low of $5.41 and a 12-month high of $12.49. The stock has a market cap of $699.64 million, a price-to-earnings ratio of -3.24 and a beta of 0.25. The business has a 50 day moving average of $10.26 and a 200-day moving average of $9.05. The company has a quick ratio of 5.12, a current ratio of 5.12 and a debt-to-equity ratio of 0.02.

Kura Oncology (NASDAQ:KURA) last posted its earnings results on Tuesday, November 4th. The company reported ($0.85) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.28). Kura Oncology had a negative return on equity of 65.42% and a negative net margin of 208.48%.The business had revenue of $20.75 million for the quarter, compared to analyst estimates of $17.48 million. On average, equities research analysts expect that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.

Analyst Ratings Changes

Several analysts recently commented on the stock. JMP Securities reaffirmed a “market outperform” rating and set a $24.00 target price on shares of Kura Oncology in a report on Monday, October 20th. Leerink Partners set a $20.00 price objective on shares of Kura Oncology and gave the stock an “outperform” rating in a research report on Tuesday, January 13th. UBS Group boosted their price objective on Kura Oncology from $14.00 to $16.00 and gave the stock a “buy” rating in a report on Friday, November 14th. Wedbush reaffirmed an “outperform” rating and issued a $38.00 target price (up previously from $36.00) on shares of Kura Oncology in a research report on Friday, November 14th. Finally, HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Kura Oncology in a report on Tuesday, January 13th. Nine analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $28.00.

Key Kura Oncology News

Here are the key news stories impacting Kura Oncology this week:

• Neutral Sentiment: Recent analyst activity is mixed — several firms (JMP, Leerink, HC Wainwright) maintain positive ratings and high price targets while others (Zacks, Weiss) issued negative views. The consensus remains a “Moderate Buy” but with divergent opinions that can sustain volatility for the stock. Analyst Coverage Summary
• Neutral Sentiment: Institutions hold large positions and some have increased stakes (Vanguard, EcoR1, Jacobs Levy, Geode, Qube Research). Significant institutional ownership can cushion price moves, though it also means bigger blocks could trade. Institutional Holdings Detail
• Negative Sentiment: Multiple insider sales reported on Jan. 27–28: SVP Teresa Brophy Bair sold 11,208 shares; Mollie Leoni sold 8,180; Thomas J. Doyle (SVP) sold 7,142; Brian T. Powl sold 6,414; COO Kathleen Ford sold 1,813; and Francis Burrows sold 1,311 — all at about $8.46 per share. The cluster of executive sales (reductions of ~1–4.7% of post-trade holdings for each insider) is weighing on sentiment because coordinated or same‑day sales by multiple insiders often trigger investor concern about near-term outlook or liquidity needs. Insider Trades Report

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in KURA. EcoR1 Capital LLC raised its position in shares of Kura Oncology by 59.1% in the second quarter. EcoR1 Capital LLC now owns 4,200,000 shares of the company’s stock valued at $24,234,000 after buying an additional 1,559,702 shares in the last quarter. Jacobs Levy Equity Management Inc. increased its stake in Kura Oncology by 101.6% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 2,224,590 shares of the company’s stock worth $19,688,000 after acquiring an additional 1,121,228 shares during the period. Qube Research & Technologies Ltd increased its stake in Kura Oncology by 63.0% during the 2nd quarter. Qube Research & Technologies Ltd now owns 1,911,886 shares of the company’s stock worth $11,032,000 after acquiring an additional 738,761 shares during the period. Acadian Asset Management LLC raised its holdings in Kura Oncology by 163.6% in the 2nd quarter. Acadian Asset Management LLC now owns 870,903 shares of the company’s stock valued at $5,022,000 after acquiring an additional 540,482 shares in the last quarter. Finally, Sector Gamma AS bought a new stake in shares of Kura Oncology during the 3rd quarter valued at $3,880,000.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.